Trial Profile
Prospective Non Interventional Study of Cabozantinib Tablets in Adults With Advanced Renal Cell Carcinoma Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Jul 2023
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- Acronyms CASSIOPE
- Sponsors Ipsen
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 12 Aug 2022 Status changed from active, no longer recruiting to completed.
- 16 Mar 2022 Status changed from recruiting to active, no longer recruiting.